1-((3S,4S)-4-Amino-1-(4-substituted-1,3,5-triazin-2-yl) pyrrolidin-3-yl)-5,5-difluoropiperidin-2-one inhibitors of DPP-4 for the treatment of type 2 diabetes
摘要:
A 3-amino-4-substituted pyrrolidine series of dipeptidyl peptidase IV (DPP-4) inhibitors was rapidly developed into a candidate series by identification of a polar valerolactam replacement for the lipophilic 2,4,5-trifluorophenyl pharmacophore. The addition of a gem-difluoro substituent to the lactam improved overall DPP-4 inhibition and an efficient asymmetric route to 3,4-diaminopyrrolidines was developed. Advanced profiling of a subset of analogs identified 5o with an acceptable human DPP-4 inhibition profile based on a rat PK/PD model and a projected human dose that was suitable for clinical development. (C) 2011 Elsevier Ltd. All rights reserved.
The invention provides compounds of formula (1),
and the pharmaceutically acceptable salt thereof, wherein R
1
, n and R
2
are as described herein; compositions thereof; and uses thereof.
[EN] COMPOUNDS FOR THE TREATMENT OF METABOLIC DISORDERS<br/>[FR] COMPOSÉS POUR LE TRAITEMENT DE TROUBLES MÉTABOLIQUES
申请人:PROSIDION LTD
公开号:WO2010103335A1
公开(公告)日:2010-09-16
The present invention is directed to therapeutic compounds which have activity as agonists of GPR119 and are useful for the treatment of metabolic disorders including type II diabetes.
本发明涉及具有 GPR119 激动剂活性的治疗化合物,适用于治疗代谢性疾病,包括Ⅱ型糖尿病。
MCM-Silylamine Pd(II)Complex: A Heterogeneous Catalyst for Selective Azide Reductions
作者:M. Lakshmi Kantam、N. Sreeniwasa Chowdari、Ateeq Rahman、B. M. Choudary
DOI:10.1055/s-1999-2846
日期:1999.9
Palladium complex immobilized on MCM-41 catalyses the reduction of alkyl, aryl and arylsulfonyl azides to the corresponding amines in excellent yields under mild conditions.
of the replacement of molecular moieties (carbamates vs. urea) that drive self-assembly for two organogelators with an identical C2 symmetric molecular structure is described. The main properties of the gels obtained from the urea-based organogelators are also discussed. The proposed organogelators are chiral molecules and are able to express chirality also at the supramolecular level, thus allowing
The overall stabilities of the bis complexes [ML2]2+ decrease in the order cis-cptn > cis-dap > trans-cptn > ampy > trans-dap. The considerably lower stabilities of the ampy complexes as compared to the corresponding cis-dap complexes indicate metal binding to the two primary amino groups of the latter ligand. This was supported by molecularmechanicscalculations (CuII and CoIII complexes) and confirmed